Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Camacho

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Physical Review Letters|May 21, 2019
Cosmological Constraints from Multiple Probes in the Dark Energy SurveyT M C Abbott, A Alarcon, S Allam, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Physical Review Letters|May 21, 2019
Cosmological Constraints from Multiple Probes in the Dark Energy SurveyT M C Abbott, A Alarcon, S Allam, et al.
Pageof 10